282 related articles for article (PubMed ID: 18040242)
1. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
Falkenstein IA; Cheng L; Freeman WR
Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
[TBL] [Abstract][Full Text] [Related]
2. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
Utman SA; Dhillon B
Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
[No Abstract] [Full Text] [Related]
3. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
4. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
Lee K; Yang H; Lim H; Lew HM
Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
[TBL] [Abstract][Full Text] [Related]
7. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
9. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
10. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection.
Im L; Allingham RR; Singh I; Stinnett S; Fekrat S
J Glaucoma; 2008 Mar; 17(2):128-32. PubMed ID: 18344759
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
13. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
14. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
15. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
16. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
17. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
19. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
[TBL] [Abstract][Full Text] [Related]
20. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.
Good TJ; Kimura AE; Mandava N; Kahook MY
Br J Ophthalmol; 2011 Aug; 95(8):1111-4. PubMed ID: 20702430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
